目的 :评价采用 3种方案治疗急性脑梗死患者的药物经济学效果 ,寻求临床最佳治疗方案。方法 :我院 2 0 0 1年 5月～ 2 0 0 3年5月住院病例中配对入选的急性脑梗死患者共 60例 ,采用重组组织型纤溶酶原激活物 (rtPA)动脉溶栓、静脉溶栓和丹参类药静滴 3种治疗方案 ,运用药物经济学的成本 效果分析方法进行评价。结果 :发病 2 1d静脉溶栓组的成本效果比最低 ,发病 6个月显示动脉溶栓组更经济。结论 :rtPA溶栓治疗急性脑梗死不仅有良好的疗效 ,而且从药物经济学的角度来考虑也是合理的。 OBJECTIVE: To evaluate the pharmacological effects of three kinds of regimens in patients with acute cerebral infarction and seek the best clinical treatment plan. Methods: A total of 60 patients with acute cerebral infarction matched for hospitalization from May 2001 to May 2003 in our hospital were treated with recombinant tissue plasminogen activator (rtPA) Intravenous thrombolysis and Danshen class medicine intravenous infusion of three kinds of treatment programs, the use of cost-effectiveness analysis of drug economics methods for evaluation. Results: The cost-effective rate of intravenous thrombolytic group was the lowest at 21 days after onset, and the thrombolytic group was more economical at 6 months after onset. Conclusion: rtPA thrombolytic therapy of acute cerebral infarction not only has a good effect, but also from the perspective of pharmacoeconomics is reasonable.